Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab). The approval applies to the first-line treatment of adults with unresectable or metastatic hepatocellular carcinoma (HCC), the most common type of primary liver cancer. This decision is based on findings from the global Phase … Bristol Myers Scores FDA Approval for Opdivo-Yervoy Combination as First-Line HCC Therapy Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.